On June 17, CHIATAI TIANQING's Class 1 innovative anti-tumor drug, Citrate Efonak Capsules (TQ-B3139), was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not received anaplastic lymphoma kinase (ALK) inhibitor therapy.
On June 17, Merck announced that the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda, K drug) has been approved by the FDA for use in combination with standard chemotherapy (carboplatin and paclitaxel) to treat patients with primary advanced or recurrent endometrial cancer. This means that Keytruda has become the first-line immunotherapy in the field of endometrial cancer that is agnostic to mismatch repair status.On June 17, Rongchang Bio (Stock Code: 688331.SH / 09995.HK) announced that a new indication for Telitacicept has been approved for clinical use in China, intended for IgG4-related disease (IgG4-RD) patients at risk of relapse.On June 17, the official website of the National Medical Products Administration (NMPA) showed that Shenghe Pharmaceutical's Ruietinib Mesylate Tablets had been approved for marketing. The indication is for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed during or after prior EGFR-TKI treatment and whose disease has been confirmed by testing to carry the EGFR T790M mutation.Investment and Financing in PharmaceuticalsRecently, Leman Biotech Co., Ltd., a biotechnology company focused on the research, development, production, and commercialization of innovative drugs for novel cancer immunotherapy, announced that it has completed two rounds of new financing: an angel+ round and an angel++ round, totaling 50 million yuan. In addition, Leman Biotech and its metabolically enhanced CAR-T project have successively received various grants amounting to approximately 20 million yuan. To date, Leman Biotech has cumulatively obtained about 150 million yuan in angel financing and project funding. This round of financing will primarily be used for the IND application of metabolically enhanced CAR-T cell therapy drugs, accelerating the clinical research of metabolically enhanced cell therapy drugs targeting solid tumors.Technology-Driven Drug Research
Recently, the research group of Li Tiehai from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, published a research paper titled "Integrated chemoenzymatic synthesis of a comprehensive sulfated ganglioside glycan library to decipher functional sulfoglycomics and sialoglycomics" in the journal Nature Chemistry. In this study, the research team overcame the challenges of preparing complex glycans by integrating chemical and enzymatic synthesis methods, achieving the effective synthesis of a glycan library comprising 65 sulfated and non-sulfated ganglioside oligosaccharides. They also utilized high-throughput glycan microarray technology to analyze the structure-function relationships between this oligosaccharide library and various disease-related proteins.
[1]Xu, Z., Liu, Y., Liu, J. et al. Integrated chemoenzymatic synthesis of a comprehensive sulfated ganglioside glycan library to decipher functional sulfoglycomics and sialoglycomics. Nat. Chem. 16, 881–892 (2024). https://doi.org/10.1038/s41557-024-01540-x
